Opticul Diagnostics

Company Overview

Snapshot

Founded in December 2007 by Gallya Gannot and Israel Gannot, Opticul Diagnostics operated with 1–10 employees. The company raised $870,000 across four funding rounds from three investors. In September 2014, BATM invested in the company.

Business overview

Opticul Diagnostics is an in vitro diagnostics device company specializing in easy and low-cost clinical laboratory and point-of-care microorganism identification solutions. The company's core technology enables specific, sensitive, and rapid identification without the use of reagents. Its flagship product, Optidet, identifies microorganisms immediately from a primary culture plate within minutes of sample application. Opticul Diagnostics operates within the Health Tech & Life Sciences sector, focusing on medical devices and diagnostics for laboratories and healthcare providers in markets such as the United States.

Strategic signal

In September 2014, BATM announced an investment of up to $450,000 in Opticul Diagnostics. This investment signaled strategic validation for Opticul's reagent-free microorganism identification technology, highlighting its potential to streamline clinical laboratory processes and enhance rapid diagnostics. For investors, this indicated a strategic alignment with a recognized player in medical technology, suggesting confidence in Opticul's market approach and product development.

Company Intelligence Q&A

What is Opticul Diagnostics' primary focus?

Opticul Diagnostics develops in vitro diagnostics devices for easy and low-cost clinical laboratory and point-of-care microorganism identification without the use of reagents.

When was Opticul Diagnostics founded?

Opticul Diagnostics was founded in December 2007 by Gallya Gannot and Israel Gannot.

Which company invested in Opticul Diagnostics in September 2014?

In September 2014, BATM invested in Opticul Diagnostics.

What is the Optidet device?

The Optidet device by Opticul Diagnostics identifies microorganisms immediately from a primary culture plate at the clinical lab within minutes of applying the sample to a disposable/removable unit.

What was a key development for Opticul Diagnostics in March 2012?

In March 2012, Opticul Diagnostics was developing a bacteria detection device intended for FDA approval.